CRDL Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 19:53):
Our systems believe the stock currently is undervalued by 0.16% compare to its pairs and should correct upwards.

Stats
Dagens volum	148 597
Gjennomsnittsvolum	507 135
Markedsverdi	136.99M
EPS	$-0.120 ( Q4 \| 2024-04-01 )
Neste inntjeningsdato	( $-0.0900 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.84 (Sector) 42.63 (Industry) 0
ATR14	$0.00700 (0.35%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX 0.71%

AKAN -3.24%

ALIM -0.54%

AMPH -4.55%

AMYT 0.00%

ANIP -0.73%

AQST -6.73%

ASRT 0.40%

ATNX 0.00%

AVDL -2.17%

AYTU -3.09%

BFRI -2.00%

BGXX 8.21%

CLVR 0.00%

COLL 1.02%

CPIX -1.31%

CRDL -1.71%

CRON -1.93%

CYTH -3.40%

DCPH 0.00%

DERM -3.65%

DRRX 0.82%

DVAX -0.80%

EGRX -2.68%

EMBC -1.96%

EMBCV -9.33%

EOLS 0.88%

ESPR 6.31%

EVOK -4.54%

FLGC -4.82%

FLXN 0.00%

GHSI -1.68%

HCM 2.51%

HROW 0.91%

HUGE -3.75%

IMCC -3.78%

INCR 1.99%

IRWD 0.92%

ITCI -2.85%

IXHL 0.34%

JUPW 11.76%

KALA -1.97%

KIN 0.11%

KMDA -1.20%

LNTH -0.77%

NBIX 1.15%

NEPT 0.00%

NLTX 1.45%

OGI 0.32%

OPTN 1.91%

ORGO -2.50%

PAHC 1.97%

PCRX 0.45%

PETQ 1.06%

PLXP 0.00%

PPD 0.00%

PROC -0.32%

PRPH -3.35%

PTPI -3.49%

RDHL -0.62%

RDUS 0.65%

REPH -0.48%

RGC -5.03%

RMTI -3.98%

SCTL 0.92%

SCYX -4.01%

SIGA -0.82%

SISI -13.85%

SNDL 0.52%

SNOA 7.35%

SSIC -2.79%

SUPN -0.90%

SXTC 0.90%

THTX 0.70%

TKNO -10.22%

TLGT -13.85%

TLRY 1.21%

TXMD 5.90%

TYHT -3.90%

UPC 3.75%

VTRS -0.56%

ZYNE 2.36%

Korrelasjon (AI algo v.1.1b): Undervalued: 0.16% $1.988 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: 0.21 (neutral)

Kort: -0.37 (neutral)

Signal:(50.152) Neutral

Cardiol Therapeutics Inc. Korrelasjon

10 Mest positive korrelasjoner
OZEM	1
JDZG	0.968
COOP	0.934
IBKR	0.928
APXI	0.922
INCR	0.921
QNST	0.918
SLMBP	0.917
EVER	0.917
SHMDW	0.916

10 Mest negative korrelasjoner
GP	-0.916
CVRX	-0.914
DALN	-0.911
LCFY	-0.909
GPRO	-0.906
SYPR	-0.9
OSUR	-0.897
FUV	-0.896
CCRN	-0.892
SABS	-0.892

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Cardiol Therapeutics Inc. Korrelasjon - Valuta/Råvare

-0.27
( neutral )

0.02
( neutral )

0.00
( neutral )

-0.14
( neutral )

0.00
( neutral )

-0.46
( neutral )

Cardiol Therapeutics Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-248 355 (0.00 %)
EPS:	$-0.440

FY	2023
Omsetning:	$0
Bruttogevinst:	$-248 355 (0.00 %)
EPS:	$-0.440

FY	2022
Omsetning:	$0
Bruttogevinst:	$-219 908 (0.00 %)
EPS:	$-0.490

Financial Reports:

No articles found.

Cardiol Therapeutics Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.